FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES
代谢型谷氨酸受体亚型的功能
基本信息
- 批准号:2460550
- 负责人:
- 金额:$ 23.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-08-01 至 2000-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The hippocampus plays an important role in a number of normal
physiological processes and in pathological conditions, including
Alzheimer's disease and epilepsy. Development of a complete understanding
of the molecular and cellular mechanisms of regulation of synaptic
function in the hippocampus could lead to new strategies for treatment of
these disorders. Until recently, it was thought that all of the actions of
glutamate, the major excitatory neurotransmitter in the hippocampus, were
mediated by activation of ligand-gated cation channels. However, it is now
clear that glutamate also activates metabotropic glutamate receptors
(mGluRs), that are coupled to effector systems through GTP binding
proteins. mGluRs play a number of important roles in regulating cell
excitability and synaptic transmission in the hippocampus. However, the
precise physiological roles of the different mGluR subtypes are not known.
A complete understanding of both normal and pathological hippocampal
function will require a detailed understanding of the roles of mGluRs in
regulating hippocampal physiology. Eight mGluR subtypes have been cloned
and these receptors have been classified into three major groups. Many of
the physiolological roles of group I mGluRs (mGluR1 and mGluR5) in the
hippocampus have been defined, but less is known about the physiological
roles of the group II (mGluR2 and mGluR3) and group III (mGluRs 4, 6, 7,
and 8) mGluRs. A series of studies is proposed that is aimed at
determining the localization and physiological roles of group II and group
III mGluRs in the hippocampus and the cellular mechanisms by which
activation of these receptors modulates hippocampal function. Patch clamp
recordings in hippocampal slices and studies of mGluR pharmacology in
expression systems will be used to test the hypothesis that a group II
mGluR serves as an autoreceptor at the perforant path synapses. mGluR2 and
mGluR3-specific antibodies will then be used for immunocytochemistry with
electron microscopy (immuno-EM) to definitively determine whether mGluR2
and/or mGluR3 is presynaptically localized at these synapses. Immuno-EM
will then be used to test the hypothesis that mGluR4a is localized
postsynaptically and mGluR7 presynaptically on hippocampal neurons. Patch
clamp recordings in hippocampal slices and studies of mGluR4a and mGluR7
pharmacology in expression systems will then be used to test the
hypothesis that these receptors play distinct pre- and postsynaptic roles
in the hippocampus. In addition to advancing our knowledge of hippocampal
function, these studies will lead to a more complete understanding of the
physiology and pharmacology of the mGluR family. Glutamate is the major
excitatory neurotransmitter in the central nervous system and
glutamatergic synapses are widespread throughout the brain. Thus, the
mGluRs are likely to play important roles in various aspects of brain
function. Developing an understanding of the physiological roles of each
mGluR subtype will ultimately lead to advances in a number of areas of
neurobiology.
海马体在许多正常的
生理过程和病理条件,包括
老年痴呆症和癫痫。全面理解的发展
突触调节的分子和细胞机制
海马体的功能可能会导致新的治疗策略,
这些紊乱。直到最近,人们还认为,
谷氨酸是海马体中主要的兴奋性神经递质,
通过激活配体门控阳离子通道介导。但现在
谷氨酸也激活代谢型谷氨酸受体
(mGluRs),其通过GTP结合与效应子系统偶联
proteins. mGluRs在调节细胞凋亡中起重要作用,
兴奋性和海马体中的突触传递。但
不同mGluR亚型的精确生理作用尚不清楚。
完整了解正常和病理海马
功能将需要详细了解mGluRs的作用,
调节海马体的生理机能已克隆了八种mGluR亚型
这些受体被分为三大类。许多
I组mGluR(mGluR 1和mGluR 5)在糖尿病中的生理作用
海马已经被定义,但对海马的生理功能知之甚少。
组II(mGluR 2和mGluR 3)和组III(mGluR 4,6,7,
和8)mGluRs。提出了一系列研究,旨在
确定II组和II组的定位和生理作用,
III海马中的mGluRs和细胞机制,
这些受体的激活调节海马的功能。膜片钳
海马切片中的记录和研究mGluR药理学,
表达系统将被用来测试的假设,第二组
mGluR在穿通通路突触处充当自身受体。mglur 2和
然后将mGluR 3特异性抗体用于免疫细胞化学,
电子显微镜(免疫EM),以明确确定是否mGluR 2
和/或mGluR 3在突触前定位于这些突触。免疫电镜
然后将用于检验mGluR 4a定位于
突触后和mGluR 7突触前对海马神经元的影响。 贴片
海马脑片钳夹记录及mGluR 4a和mGluR 7的研究
表达系统中的药理学将用于测试
这些受体在突触前和突触后发挥不同作用的假说
在海马区。除了提高我们对海马的认识,
功能,这些研究将导致更全面的了解
mGluR家族的生理学和药理学。 谷氨酸是主要的
中枢神经系统中的兴奋性神经递质,
神经元突触遍布整个大脑。因此
mGluRs可能在脑的各个方面发挥重要作用
功能 发展对每一种生理作用的理解
mGluR亚型将最终导致在一些领域的进展,
神经生物学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
P Jeffrey Conn其他文献
Promise of mGluR2/3 activators in psychiatry
mGluR2/3 激活剂在精神病学中的前景
- DOI:
10.1038/npp.2008.156 - 发表时间:
2008-12-12 - 期刊:
- 影响因子:7.100
- 作者:
P Jeffrey Conn;Carrie K Jones - 通讯作者:
Carrie K Jones
Ethanol-Induced Adaptations to Inhibitory Microcircuits in the Mouse Prefrontal Cortex
- DOI:
10.1016/j.biopsych.2021.02.313 - 发表时间:
2021-05-01 - 期刊:
- 影响因子:
- 作者:
Max Joffe;Anthony Ferranti;Danny Winder;P Jeffrey Conn - 通讯作者:
P Jeffrey Conn
Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?
自闭症谱系障碍的药物治疗:新兴方法会产生新的治疗方法吗?
- DOI:
10.1038/npp.2015.259 - 发表时间:
2015-12-10 - 期刊:
- 影响因子:7.100
- 作者:
Rocco G Gogliotti;P Jeffrey Conn - 通讯作者:
P Jeffrey Conn
P Jeffrey Conn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('P Jeffrey Conn', 18)}}的其他基金
Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
- 批准号:
10531546 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
- 批准号:
10305625 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾镇痛疗法
- 批准号:
10450295 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
发现 mGlu 受体 PAM 用于治疗精神分裂症
- 批准号:
10063834 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾性镇痛治疗药物
- 批准号:
10477066 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
新型 mGlu5 负变构调节剂作为一流的非成瘾镇痛疗法
- 批准号:
10581793 - 财政年份:2019
- 资助金额:
$ 23.63万 - 项目类别:
Development of an M1 PAM experimental therapeutic for schizophrenia
开发治疗精神分裂症的 M1 PAM 实验疗法
- 批准号:
9140071 - 财政年份:2015
- 资助金额:
$ 23.63万 - 项目类别:
Development of mGIuR5 NAMS for Treatment of Major Depression
mGIuR5 NAMS 的开发用于治疗重度抑郁症
- 批准号:
8434427 - 财政年份:2013
- 资助金额:
$ 23.63万 - 项目类别:
Development of mGIuR5 NAMS for Treatment of Major Depression
用于治疗重度抑郁症的 mGIuR5 NAMS 的开发
- 批准号:
8603872 - 财政年份:2013
- 资助金额:
$ 23.63万 - 项目类别:
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3
mGluR3 选择性负变构调节剂的发现和优化
- 批准号:
8726488 - 财政年份:2012
- 资助金额:
$ 23.63万 - 项目类别:
相似海外基金
Paracrine and autocrine IL-6 as drivers of treatment resistance in medulloblastoma
旁分泌和自分泌 IL-6 作为髓母细胞瘤治疗抵抗的驱动因素
- 批准号:
468060 - 财政年份:2022
- 资助金额:
$ 23.63万 - 项目类别:
Operating Grants
Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML)
靶向自分泌肝细胞生长因子 (HGF) 的产生作为急性髓系白血病 (AML) 的治疗方式
- 批准号:
10589002 - 财政年份:2022
- 资助金额:
$ 23.63万 - 项目类别:
Autocrine and paracrine podocyte signals decrease glomerular function/health in aged kidneys
自分泌和旁分泌足细胞信号会降低老年肾脏的肾小球功能/健康
- 批准号:
10698100 - 财政年份:2022
- 资助金额:
$ 23.63万 - 项目类别:
Elucidating the role of autocrine TNF signaling in maintaining human regulatory T cell identity
阐明自分泌 TNF 信号传导在维持人类调节性 T 细胞身份中的作用
- 批准号:
BB/W001055/1 - 财政年份:2022
- 资助金额:
$ 23.63万 - 项目类别:
Research Grant
Autocrine Action of Elevated FGF-21 Contributing to Skeletal Muscle Atrophy in Response to Mitochondrial Dysfunction
FGF-21 升高的自分泌作用导致线粒体功能障碍引起的骨骼肌萎缩
- 批准号:
10615236 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:
Rôle autocrine des exosomes sécrétés par le muscle dans un contexte de diabète de type 2
2 型糖尿病背景下肌肉中外泌体的自分泌作用
- 批准号:
466812 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:
Studentship Programs
Autocrine Action of Elevated FGF-21 Contributing to Skeletal Muscle Atrophy in Response to Mitochondrial Dysfunction
FGF-21 升高的自分泌作用导致线粒体功能障碍引起的骨骼肌萎缩
- 批准号:
10296083 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:
Autocrine Action of Elevated FGF-21 Contributing to Skeletal Muscle Atrophy in Response to Mitochondrial Dysfunction
FGF-21 升高的自分泌作用导致线粒体功能障碍引起的骨骼肌萎缩
- 批准号:
10469480 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:
Mitochondrial reactive oxygen species act as autocrine neuromodulators in retinal ganglion cells
线粒体活性氧在视网膜神经节细胞中充当自分泌神经调节剂
- 批准号:
10157645 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:
Mitochondrial reactive oxygen species act as autocrine neuromodulators in retinal ganglion cells
线粒体活性氧在视网膜神经节细胞中充当自分泌神经调节剂
- 批准号:
10343744 - 财政年份:2021
- 资助金额:
$ 23.63万 - 项目类别:














{{item.name}}会员




